Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Nitta, Masayuki ^a   Kozono, David ^a,b   Kennedy, Richard ^c   Stommel, Jayne ^a   Ng, Kimberly ^a   Zinn, Pascal O ^a   Kushwaha, Deepa ^a   Kesari, Santosh ^d   Furnari, Frank ^e   Hoadley, Katherine A ^f   Chin, Lynda ^a   Depinho, Ronald A ^a   Cavenee, Webster K ^e   D'Andrea, Alan ^a   Chen, Clark C ^a,g  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^c Almac Sciences   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOPROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REACTIVE OXYGEN METABOLITE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER THERAPY; CELL ACTIVITY; CONTROLLED STUDY; DNA STRAND BREAKAGE; DOWN REGULATION; ENZYME INHIBITION; EXCISION REPAIR; GENE ACTIVATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PROTEIN TARGETING; PROTEIN VARIANT; RNA ANALYSIS; DNA DAMAGE; DNA REPAIR; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; RADIATION DOSE; SURVIVAL; TREATMENT OUTCOME; TUMOR CELL LINE;

CELL LINE, TUMOR; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMANS; OXIDATIVE STRESS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION TOLERANCE; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77956294131     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010767     Document Type: Article

References (33)

1. Cancer Genome Atlas Research N (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
2. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
3. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. New England Journal of Medicine 353: 2012-2024.
4. Luo J, Solimini NL, Elledge SJ (2009) Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136: 823-837.
5. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
6. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727-7731.
7. Weinstein IB (2002) Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
8. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 287-290.
9. Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, et al. (2005) Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7: 575-589.
10. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, et al. (1999) Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274: 7936-7940.
11. Denko NC, Giaccia AJ, Stringer JR, Stambrook PJ (1994) The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci U S A 91: 5124-5128.
12. Friedberg E, Walker G, Siede W, Wood R, Schultz R, et al. (2006) DNA repair and mutagenesis. Washington DC: ASM Press. 1118 p.
13. Jackson SP, Bartek J (2009) The DNA-damage response in human biology and disease. Nature 461: 1071-1078.
14. Helbock HJ, Beckman KB, Ames BN (1999) 8-Hydroxydeoxyguanosine and 8- hydroxyguanine as biomarkers of oxidative DNA damage. Methods Enzymol 300: 156-166.
15. Yoon JH, Iwai S, O'Connor TR, Pfeifer GP (2003) Human thymine DNA glycosylase (TDG) and methyl-CpG-binding protein 4 (MBD4) excise thymine glycol (Tg) from a Tg:G mispair. Nucleic Acids Res 31: 5399-5404.
16. Hazra TK, Das A, Das S, Choudhury S, Kow YW, et al. (2007) Oxidative DNA damage repair in mammalian cells: a new perspective. DNA Repair (Amst) 6: 470-480.
17. Haince JF, Rouleau M, Hendzel MJ, Masson JY, Poirier GG (2005) Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy. Trends Mol Med 11: 456-463.
18. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
19. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, et al. (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
20. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, et al. (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917.
21. Rassool FV, Gaymes TJ, Omidvar N, Brady N, Beurlet S, et al. (2007) Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res 67: 8762-8771.
22. Harper JW, Elledge SJ (2007) The DNA damage response: ten years after. Mol Cell 28: 739-745.
23. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. Journal of Biological Chemistry 272: 2927-2935.
24. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864-870.
25. Sallmyr A, Fan J, Rassool FV (2008) Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 270: 1-9.
26. Kim HW, Murakami A, Williams MV, Ohigashi H (2003) Mutagenicity of reactive oxygen and nitrogen species as detected by co-culture of activated inflammatory leukocytes and AS52 cells. Carcinogenesis 24: 235-241.
27. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12: 7242-7251.
28. Tudek B (2007) Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med 28: 258-275.
29. Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, et al. (2010) Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1 p98. Cancer Cell 17: 98-110.
30. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
31. Mukherjee B, McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, et al. (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69: 4252-4259.
32. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ (1998) Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A 95: 5724-5729.
33. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A (2009) CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 8: 24.